The FDA worked with the U.S. Department of Justice to place Getinge manufacturing sites under consent decree in 2015 and added the IABP manufacturing site in 2022. This action allows additional FDA oversight, an independent auditor, inspections, and updates on progress made toward addressing quality and safety concerns. At this time, the cardiopulmonary bypass and IABP facilities have not met the requirements to have the consent decree lifted.